Please assess the completion status of the following clinical trial:

Trial Title: Malaria: Relative Bioavailability and Food Effect of DSM265

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
1. Subjects or their legally authorized representative must voluntarily sign and date each informed consent, approved by an Independent Ethics Committee(IEC) / Institutional Review Board (IRB), prior to the initiation of any screening or study-specific procedures.~2. Male or female between 18 and 55 years of age inclusive at the time of screening.~3. Body Mass Index (BMI) is ≥ 18.0 to ≤ 29.9 kg/m2 after rounding to the tenths decimal. BMI is calculated as weight in kg divided by the square of height measured in meters.~4. Females must be of Non-Childbearing Potential as defined below~   Females do not need to use birth control during or following study drug treatment if considered of non-childbearing potential due to meeting any of the following criteria:~  * Postmenopausal, age ≤ 55 years with no menses for 12 or more months without an alternative medical cause AND an follicle stimulating hormone (FSH) level \> 40 IU/L.~  * Permanently surgically sterile (bilateral oophorectomy, bilateral salpingectomy, or hysterectomy).~5. Female who is not pregnant, breastfeeding, or considering becoming pregnant during the study or for approximately 120 days after the last dose of study drug.~6. Male subjects who are sexually active with a female partner of childbearing potential, must agree to use condoms, even if the male subject has undergone a successful vasectomy, from Study Day 1 through 120 days after the last dose of study drug. His female partner(s) must also use at least one of the following methods of birth control:~   * Combined (oestrogen and progestogen containing) hormonal birth control (oral, intravaginal, injectable, transdermal) associated with inhibition of ovulation initiated at least 30 days prior to study Baseline Day 1.~  * Progestogen-only hormonal birth control (oral, injectable, implantable) associated with inhibition of ovulation initiated at least 30 days prior to study Baseline Day 1.~  * Bilateral tubal occlusion/ligation.~  * Intrauterine device (IUD).~  * Intrauterine hormone-releasing system (IUS).~7. Male who is not considering fathering a child or donating sperm during the study or for approximately 120 days after the last dose of study drug.~8. Laboratory values meet the following criteria:~   * Serum aspartate transaminase (AST) and alanine transaminase (ALT) ≤ the upper limit of normal (ULN) at the Screening Visit and upon initial confinement.~  * Negative test result for hepatitis A virus immunoglobulin M (HAV-IgM), hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody (Ab) and human immunodeficiency virus (HIV) at screening visit.~  * Negative screen for drugs of abuse, alcohol or cotinine at screening and upon initial confinement.~  * For non-postmenopausal female subjects, a negative urine pregnancy test at the screening visit and a negative serum pregnancy test upon initial confinement and prior to the first dose of study drug.~  * No other laboratory results that the investigator determines are clinically significant.~  * Platelets greater than or equal to the lower limit of normal.~9. No clinically significant ECG abnormalities including~   * No evidence of 2nd or 3rd degree AV block at screening visit and upon initial confinement.~  * QT interval corrected for heart rate (QTc) using Fridericia's correction formula (QTcF) is ≤ 430 msec (males) or ≤ 450 msec (females) at screening visit and upon initial confinement.~10. A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead ECG.~11. No history of: epilepsy, any clinically significant cardiac, respiratory (except mild asthma as a child), renal, hepatic, gastrointestinal, hematologic or psychiatric disease or disorder, or any uncontrolled medical illness.~12. No history of any clinically significant sensitivity or allergy to any medication or food.~13. No history of or active medical condition(s) or surgical procedure(s) that might affect gastrointestinal motility, pH, or absorption \[e.g., Crohn's disease, celiac disease, gastroparesis, short bowel syndrome, gastric surgery (except pyloromyotomy for pyloric stenosis during infancy), cholecystectomy, vagotomy, bowel resection\].~14. No evidence of dysplasia or history of malignancy (including lymphoma and leukemia) other than successfully treated non-metastatic cutaneous squamous cell, basal cell carcinoma or localized carcinoma in situ of the cervix.~15. No history of any clinically significant illness/infection/major febrile illness, hospitalization, or any surgical procedure within 30 days prior to the first dose of study drug.~16. Has not donated blood (including plasmapheresis), lost ≥ 550 mL blood volume, or received a transfusion of any blood product within 8 weeks prior to study drug administration.~17. No consumption of alcohol, grapefruit products, Seville oranges, starfruit products or quinine/tonic water within the 72-hour period prior to study drug administration.~18. No use of tobacco or nicotine-containing products within 180 days prior to the first dose of study drug.~19. No history of clinically significant (per Investigator's judgment) drug or alcohol abuse within the last 6 months.~20. Is not currently enrolled in another interventional clinical study.~21. Has not been previously enrolled in this study.~22. In the opinion of the investigator, this subject is a suitable candidate for enrollment in the study.~23. Subjects must not have been treated with any investigational drug within 30 days or 5 half-lives of the drug (whichever is longer) prior to the first dose of study drug.~24. Subject must not have received any live vaccine within 4 weeks prior to the first dose of study drug, or expected need of live vaccination during study participation including at least 4 weeks after the last dose of study drug.~25. Subject must not require any over-the-counter and/or prescription medication, vitamins and/or herbal supplements, with the exception of contraceptives or hormonal replacement therapies for females, on a regular basis.~26. Subject must not use any medications within the 2-week period prior to study drug administration.~27. Receipt of any drug by injection within 30 days or within a period defined by 5 half-lives, whichever is longer, prior to study drug administration.~28. No use of known inhibitors (e.g., ketoconazole) or inducers (e.g., carbamazepine) of cytochrome P450 3A (CYP3A) within 1 month prior to study drug administration.~29. No exposure to DSM265 within the past 90 days prior to first dose of study drug.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- DSM265-TPGS 34% SDD, 400 mg fasted (Type: EXPERIMENTAL): Spray dried dispersion (SDD) formulation, powder containing 34.25% DSM265-TPGS (tocopheryl polyethylene glycol succinate)
- DSM265-TPGS 34% SDD, 400 mg fed (Type: ACTIVE_COMPARATOR): Spray dried dispersion (SDD) formulation, powder containing 34.25% DSM265-TPGS (tocopheryl polyethylene glycol succinate)
- DSM265 25% SDD, 400 mg fasted (Type: ACTIVE_COMPARATOR): Spray dried dispersion (SDD) formulation, powder containing 25% DSM265 as free base

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete